Latest News

A novel alternate-salt capsule formulation of cabozantinib has received FDA tentative approval for advanced renal cell carcinoma, hepatocellular carcinoma, and neuroendocrine tumors.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Kay Yoon-Flannery, DO, spoke about how offering robotic mastectomy locally at AtlantiCare improved patient access.

Gedatolisib plus fulvestrant, with or without palbociclib, now holds NCCN Category 1 status for HR+, HER2- PIK3CA wild-type advanced breast cancer.

Ajay K. Nooka, MD, MPH, FACP, says the teclistamab-talquetamab combination reduced progression risk by 89% in MonumenTAL-6.

Kay Yoon-Flannery, DO, described why the lateral axillary line is her preferred incision site for single-port robotic mastectomy.

Frank McCormick, PhD, FRS, DSc (Hon), outlined the rationale for combining KRAS inhibitors with PI3K and checkpoint inhibitors to improve durability of response.

María Teresa Bourlon, MD, MSc, MS, discussed key kidney abstracts from the 2026 ASCO Meeting, including the LenCabo trial, the RAMPART trial, and the RADICAL trial.

Data from the PSMAddition trial support the approval of the radioligand-based regimen for this prostate cancer population.

Stay tuned for an in-depth discussion on navigating operational workflows and mitigating barriers to access for CAR T-cell therapy in multiple myeloma.

The regulatory decision for subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell carcinoma was based on phase 1b/2 OrigAMI-4 data.

Two hematologic oncology experts discuss operational and referral workflows, as well as barriers to access for CAR T-cell therapy in multiple myeloma.

Selinexor maintenance therapy did not significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in a phase 3 trial.

Kay Yoon-Flannery, DO, MPH, FACS, discusses da Vinci Single Port robotic mastectomy, ranging from technique and patient selection to outcomes.

Kay Yoon-Flannery, DO, MPH, FACS, explained how the da Vinci Single Port 3D visualization improves precision vs open or multiport surgery.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, predicts operational challenges as CAR T-cell therapy expands to non-oncology indications.

Frank McCormick, PhD, FRS, DSc (Hon), discussed his vision for preemptively treating KRAS-driven precancerous lesions, differences between KRAS allele subtypes, and where the field is headed over the next decade.

The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.

The UAE granted marketing authorization for nogapendekin alfa plus BCG in BCG-unresponsive NMIBC and with checkpoint inhibitors in metastatic NSCLC.

Data from a phase 1 trial validate FcRH5 as a “good target” in multiple myeloma therapy, according to Adam D. Cohen, MD.

Adding mFOLFOX6 and bevacizumab to atezolizumab cut the risk of progression or death by 58% vs atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer.

Cema-cel received RMAT and fast track designations for first-line consolidation therapy in MRD-positive large B-cell lymphoma based on phase 2 ALPHA3 data.

María Teresa Bourlon, MD, MSc, FASCO, discussed why early RadiCal trial closure and adverse effects outweigh secondary survival signals in bone-metastatic RCC.

Explore modern metastatic breast cancer care: longer survival, smarter symptom control, caregiver support, and steps to close racial treatment gaps.

María Teresa Bourlon, MD, MSc, FASCO, discussed data showing body composition and muscle loss with lenvatinib/everolimus vs cabozantinib in metastatic ccRCC.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.

Data from a first-in-human phase 1 trial assessing ISM6331 in mesothelioma and other solid tumors will be presented at the ESMO Congress 2026.

Key genitourinary oncology updates emerged from ASCO 2026, focusing on balancing efficacy and AEs.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, says equitable access to CAR T-cell therapy depends on partnership, not just center certification.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed overcoming insurance barriers to oral AML treatment access.

Final phase 3 BOND-003 Cohort C results showed a 75.5% complete response rate with cretostimogene grenadenorepvec in BCG-unresponsive NMIBC.